Investment
Lectus Therapeutics Ltd, a drug discovery and development company specialising in ion channel modulators, has been awarded £3 million under the Wellcome Trust’s Seeding Drug Discovery Initiative to identify new classes of selective potassium channel modulator drug candidates for the treatment of multiple sclerosis.
Lectus will use its LEPTICS platform technology to identify drug candidates targeting a novel mechanism of action that is anticipated to address some of the drawbacks associated with existing drugs and those currently under development. The Wellcome Trust retains the option to fund subsequent preclinical and clinical development of compounds identified under the alliance.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
